SCHEMBL6399685

SCHEMBL6399685

CCc1ccc(Nc2c(-c3nnc(NC(C)C)o3)ccc(F)c2F)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.36
PIM1 P11309 8/20 0.35
PIM2 Q9P1W9 7/20 0.35
KDR P35968 3/20 0.33
CYP3A4 P08684 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32
ADCY1 Q08828 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
FLT1 P17948 2/20 0.32
MAP2K2 P36507 2/20 0.31
MAP2K1 Q02750 2/20 0.31
TUBB4A P04350 2/20 0.31
TUBB P07437 2/20 0.31
TUBA3C P0DPH7 2/20 0.31
TUBA1B P68363 2/20 0.31
TUBA4A P68366 2/20 0.31
TUBB4B P68371 2/20 0.31
TUBB3 Q13509 2/20 0.31
TUBB2A Q13885 2/20 0.31
TUBB8 Q3ZCM7 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397573 0.89 RXFP1 (0.33) KDRRXFP1ADCY1IRAK4FLT1
SCHEMBL6207316 0.85 KDM4E (0.34) KDRFLT1
SCHEMBL6205699 0.84 MAP2K1 (0.37) KDRCYP3A4RXFP1ADCY1FLT1
SCHEMBL6398977 0.84 KDR (0.34) PIM1KDRRXFP1ADCY1FLT1
SCHEMBL6207753 0.84 MAP2K2 (0.34) KDRFLT1MAP2K2MAP2K1
SCHEMBL6207255 0.83 CHRNA7 (0.33) KDRCYP3A4FLT1
SCHEMBL6206538 0.83 ALOX12 (0.41) KDRRXFP1ADCY1FLT1MAP2K2
SCHEMBL6398804 0.83 CDC7 (0.37) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6191149 0.83 MAP2K1 (0.35) KDRRXFP1ADCY1IRAK4FLT1
SCHEMBL6186912 0.83 MAP2K1 (0.35) KDRRXFP1ADCY1IRAK4FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 ELANE 1967/4885PIM1 74/4885PIM2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.